An antigen-targeting assay for Lyme disease: Combining aptamers and SERS to detect the OspA protein

Lyme disease is the fastest growing vector-borne disease in the United States. However, current testing modalities are ill suited to detection of Lyme disease, leading to the diagnosis of many cases after treatment is effective. We present an improved, direct method Lyme disease diagnosis, where the Lyme specific biomarker Outer Surface Protein A (OspA) in clinical serum samples is identified using a diagnostic platform combining surface enhanced Raman scattering (SERS) and aptamers. Employing orthogonal projections to latent structures discriminant analysis, the system accurately identified 91% of serum samples from Lyme patients, and 96% of serum samples from symptomatic controls. In addition, the OspA limit-of-detection, determined to be 1 x 10(-4) ng/mL, is greater than four orders of magnitude lower than that found in serum samples from early Lyme disease patients. The application of this platform to detect this difficult-to-diagnose disease suggests its potential for detecting other diseases that present similar difficulties. (c) 2022 Elsevier Inc. All rights reserved.

Automated summary

Lyme disease is the fastest growing vector-borne disease in the United States. The current testing modalities are not suitable for detection, leading to delayed treatment. This study presents an improved direct method for diagnosing Lyme disease using SERS and aptamers, achieving an accuracy rate of 91% for the diagnosis of Lyme disease.